Specialists in quantifying the current and future burden of non-communicable and rare genetic diseases.
Our data-driven epidemiology generates evidence to support strategic planning and portfolio management at each stage of the drug development process, helping to bring new therapies to patients faster.
From molecule to market, our solutions can help.
Deep expertise in disease epidemiology combined with entrepreneurial vision. Our work has been widely published and peer-reviewed by world-leading experts.
Why Us?We’ve spent over a decade developing our methodology to help you ask the right questions and make the best decisions.
SolutionsWe’ve answered all kinds of questions for many different organisations, covering over 25 NCDs and rare genetic diseases in over 80 countries.
Track RecordOur experienced and multidisciplinary team brings together epidemiologists, geneticists, mathematicians, data scientists, researchers, and software engineers.
About UsHealthLumen are looking forward to discussing our work on the prevalence of rare diseases and engaging with colleagues dedicated to accelerating rare disease therapeutics at several upcoming conferences in the final quarter of this year.
ReadRallybio, a clinical-stage biotechnology company, will be presenting the findings of a genetic database analysis study conducted in partnership with HealthLumen on Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) risk across racially and ethnically diverse populations at the American Society of Human Genetics (ASHG) 2024 Annual Meeting. The conference will take place from November 5–9 2024 in Denver, Colorado.
Read“Genomics requires a form of modelling that can capture individual genetic differences and responses to therapy – a purpose to which microsimulation is eminently suited.”
This quote, from a seminal review paper by Professors Deborah Schofield and Rupendra Shrestha of Macquarie University, pioneers in applying microsimulation techniques for modelling the costs and benefits of genomic medicine, formed the basis for a fascinating recent discussion with the HealthLumen team, on the role of microsimulation modelling techniques in precision medicine.
ReadHealthLumen was recently commissioned by Movember, one of the leading charities changing the face of men’s health, to quantify the economic impact of men’s poor health for their ‘Real Face of Men’s Health’ 2024 UK Report. The study found that in 2023 the five diseases that cause the largest number of years of life lost […]
Read